{"product_id":"next-generation-cancer-diagnostics-technologies-and-global-markets","title":"Next-Generation Cancer Diagnostics: Technologies and Global Markets","description":"\u003cp\u003eNext-Generation Cancer Diagnostics: Technologies and Global Markets\u003c\/p\u003e\n\n\u003cp\u003eReport Scope:\u003c\/p\u003e\n\n\u003cp\u003eThis research report analyzes leading next-generation diagnostic technologies, including next generation sequencing (NGS), polymerase chain reaction (PCR), multiplex conventional, cell or extracellular vesicle capture, and arrays\/microfluidics. The report also discusses various liquid biopsy platforms and how these compare with tissue-based testing.\u003c\/p\u003e\n\n\u003cp\u003eThe report discusses several significant, large-scale research initiatives contributing to cancer diagnostic development. Key forces driving the market are discussed.\u003c\/p\u003e\n\n\u003cp\u003eAn in-depth analysis of key companies operating in the next-generation cancer diagnostic and technologies market is also included. The information also focuses on companies involved in developing products and emerging technologies.\u003c\/p\u003e\n\n\u003cp\u003eThe market for next-generation cancer diagnostics is analyzed in depth. The market is analyzed by cancer site (bladder, brain, breast, colorectal, cancer of unknown primary, gastric, gynecologic, hematologic, kidney, liver, lung, pan-cancer, pancreatic, prostate, melanoma, and thyroid), by test purpose (screening\/early detection, diagnosis, monitoring, therapy guidance), by test platform (arrays\/microfluidics, cell\/EV capture, multiplex conventional, PCR and NGS) and by geography (North America, Europe, Asia-Pacific, and Rest of World).\u003c\/p\u003e\n\n\u003cp\u003eThe base year for market data is 2021, with historical data provided for 2020 and 2019 and forecast data provided through 2027. Historical, base year, and forecast data are provided for each market segment of the report.\u003c\/p\u003e\n\n\u003cp\u003eReport Includes:\u003c\/p\u003e\n\n\u003cp\u003e15 data tables and 80 additional tables\u003c\/p\u003e\n\n\u003cp\u003eAn overview of the global market and technologies for next generation cancer diagnostics\u003c\/p\u003e\n\n\u003cp\u003eEstimation of the market size and analyses of global market trends, with data from 2021, estimates for 2022 and projections of compound annual growth rates (CAGRs) through 2027\u003c\/p\u003e\n\n\u003cp\u003eHighlights of the current and future market potential and quantification of next generation cancer diagnostics market based on type, application, and region\u003c\/p\u003e\n\n\u003cp\u003eDescription of arrays and microfluidics (LOAC) technologies, multiplex conventional technologies, next generation sequencing technology and polymerase chain reaction (PCR) technology\u003c\/p\u003e\n\n\u003cp\u003eAnalysis of underlying technological, environmental, legal\/regulatory, and political trends that may influence the size and nature of the market\u003c\/p\u003e\n\n\u003cp\u003eCoverage of the key initiatives and programs related to the next generation cancer diagnostics market\u003c\/p\u003e\n\n\u003cp\u003eMarket share analysis of the key companies of the industry and coverage of their proprietary technologies, strategic alliances, and other key market strategies\u003c\/p\u003e\n\n\u003cp\u003eCompany profiles of major players within the industry, including Abbott Laboratories, Illumina Inc., Becton, Dickinson and Co., and Illumina Inc.\u003c\/p\u003e","brand":"Life Science","offers":[{"title":"May, 2023 \/ 166 Pages \/ MCW16229793","offer_id":47647003050290,"sku":null,"price":6600.0,"currency_code":"USD","in_stock":true},{"title":"May, 2023 \/ 166 Pages \/ MCW16229794","offer_id":47647003083058,"sku":null,"price":6600.0,"currency_code":"USD","in_stock":true}],"url":"https:\/\/www.hardmanwell.com\/products\/next-generation-cancer-diagnostics-technologies-and-global-markets","provider":"HARDMAN AND WELL MANAGEMENT CONSULTANCIES L.L.C","version":"1.0","type":"link"}